A key challenge in studying native GLP-1 is its extremely short in vivo half-life of approximately 12 minutes, owing to rapid inactivation by dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide from GLP-1 to produce the inactive metabolite GLP-1(936)amide
However, the introduction of melanotan 2 nasal sprays offers researchers an additional option for study designs in which injections are unsuitable for reasons including: Test subjects uncomfortable with self-administering injections Fear of needles Injection site pain Poor test subject compliance Although an MT-II nasal spray has not been specifically evaluated in clinical trials, research supports the compatibility of the MT-II peptide with an intranasal format, along with a long track record of delivering peptides and protein intranasally [3]
Ong SB, Subrayan S, Lim SY, Yellon DM, Davidson SM, Hausenloy DJ
The two drugs have similar lists of potential side effects
Are there any populations who should not use Melanotan-1 or PT-141
Mounjaro vs Ozempic for PCOS In 2021, results were published from a comparison trial of Mounjaro vs Ozempic [18]